Back to News & Events

New York State Innovation Summit

NYSTAR and FuzeHub invite you to the New York State Innovation Summit on November 8-9, 2021 at the Turning Stone in Verona, NY. This multi-day event for NYS organizations that want to showcase and discover new and emerging technologies that support innovation and drive business growth. Whether you’re a startup, an economic developer, or an established manufacturer, the NYS Innovation Summit is for you.

The 2021 New York State Innovation Summit will showcase companies and researchers at the forefront of emerging technologies and new advancements in production capabilities. This event celebrates New York State leadership in technology-led economic growth with experts in biotechnology, new materials, energy innovation, and artificial intelligence that will explore current technology convergence opportunities, ways to accelerate commercialization, and issues of manufacturing sustainability.

This year’s Innovation Summit includes the New York State Commercialization Competition and speakers from top companies such as Cree, Plug Power, Velan Studios and Verizon 5G Labs.

For more information, or to register, visit nysinnovationsummit.com.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 5065
                    [post_author] => 4
                    [post_date] => 2026-09-01 14:03:32
                    [post_date_gmt] => 2026-09-01 18:03:32
                    [post_content] => 

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.

BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.

Application deadline: October 29, 2026, 5:00pm ET

For info sessions, eligibility and deadlines visit our REACH Website and FAQ.

The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.

Questions? Reach out to our program contacts or sign up for office hours:

Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here

Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here

[post_title] => BioREACH: Translational Research Funding Opportunity [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bioreach-translational-research-funding-opportunity [to_ping] => [pinged] => [post_modified] => 2026-09-04 11:55:36 [post_modified_gmt] => 2026-09-04 15:55:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5065 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3721 [post_author] => 3 [post_date] => 2021-03-29 13:10:24 [post_date_gmt] => 2021-03-29 13:10:24 [post_content] =>

BARDA DRIVe is seeking information on developments in anticoagulation drugs, assays, and management in the specific context of extracorporeal membrane oxygenation (ECMO) therapy. The intent is to identify areas of innovation that can solve the challenges posed by anticoagulation in ECMO or improve on the ways this issue is currently being addressed. BARDA will not execute any awards based on this notice. This RFI solely aims to gather knowledge on present and future capabilities and other pertinent marketplace data to strengthen BARDA’s understanding of the current developmental landscape of this field. This does not constitute a Request for Proposal (RFP). More information can be found here:
https://beta.sam.gov/opp/e9e7f046d7234dae9f14c1b38a5a20f9/view

The RFI will be open until 04 May 2021, and interested companies should submit their responses to DRIVeContracting@hhs.gov.


[post_title] => BARDA: Call for Information [post_excerpt] => BARDA DRIVe is seeking information on developments in anticoagulation drugs, assays, and management in the specific context of extracorporeal membrane oxygenation (ECMO) therapy. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => barda-call-for-information [to_ping] => [pinged] => [post_modified] => 2021-09-20 16:11:14 [post_modified_gmt] => 2021-09-20 16:11:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3721 [menu_order] => 51 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3811 [post_author] => 4 [post_date] => 2021-08-30 15:39:32 [post_date_gmt] => 2021-08-30 15:39:32 [post_content] =>

The BBCetc “From the Sources’ Mouth,” fall event is a free, virtual 3-day SBIR/STTR training with program managers from 11 federal agencies.

Each will present a 30-minute overview of their agency’s mission along with tips for creating a successful proposal. Everyone who attends will have time for Q&A as well as the opportunity to sign up for special one-on-one discussions with agency officers.

1 registration. 3 days. 11 SBIR/STTR agencies. One registration gives you access for all three days. Detailed agenda coming soon so you can choose which presenters you want to see.

Sept. 14, 2021
9:00 am - 5:00 pm (EST)
Granting Agencies
SBA, NIH, NSF, DOC-NOAA, DOE, USDA, NIAD

Sept. 15, 2021
9:00 am - 5:00 pm (EST)
Contracting Agencies
SBA, EPA, BARDA, NASA, DOT, DOEd, CDMRP

Sept. 16, 2021
9:00 am - 5:00 pm (EST)
DOD & Components
DOD, DHA, DARPA, SPARTN, NavSea, Air Force/AFWERX, DHS

Register Now

[post_title] => “From the Sources’ Mouth" SBIR/STTR training Program [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => from-the-sources-mouth-sbir-sttr-training-program [to_ping] => [pinged] => [post_modified] => 2021-09-20 16:03:09 [post_modified_gmt] => 2021-09-20 16:03:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3811 [menu_order] => 39 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4445 [post_author] => 4 [post_date] => 2024-06-10 15:37:44 [post_date_gmt] => 2024-06-10 19:37:44 [post_content] =>

Envisagenics, an AI-enabled biotechnology firm specializing in RNA splicing therapeutics, has announced the completion of its Series B funding round. This round included investments from existing supporters Third Kind Venture Capital, Empire State Development, and Red Cell Partners, as well as new strategic investor Bristol Myers Squibb, which has been collaborating with Envisagenics on oncology research since 2022.

Read more about Envisagenics Series B award here.

[post_title] => CFB Client Envisagenics Secures $25 Million Series B Funding to Advance RNA Splicing Therapeutics [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => envisagenics-secures-25-million-series-b-funding-to-advance-rna-splicing-therapeutics [to_ping] => [pinged] => [post_modified] => 2025-05-01 12:39:53 [post_modified_gmt] => 2025-05-01 16:39:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4445 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 5065 [post_author] => 4 [post_date] => 2026-09-01 14:03:32 [post_date_gmt] => 2026-09-01 18:03:32 [post_content] =>

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.

BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.

Application deadline: October 29, 2026, 5:00pm ET

For info sessions, eligibility and deadlines visit our REACH Website and FAQ.

The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.

Questions? Reach out to our program contacts or sign up for office hours:

Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here

Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here

[post_title] => BioREACH: Translational Research Funding Opportunity [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bioreach-translational-research-funding-opportunity [to_ping] => [pinged] => [post_modified] => 2026-09-04 11:55:36 [post_modified_gmt] => 2026-09-04 15:55:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5065 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 288 [max_num_pages] => 96 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

BioREACH: Translational Research Funding Opportunity

More Information

BARDA: Call for Information

More Information

“From the Sources’ Mouth” SBIR/STTR training Program

More Information

CFB Client Envisagenics Secures $25 Million Series B Funding to Advance RNA Splicing Therapeutics

More Information